U.S. Specialized REITs Stock News

Uranium Energy has seen sharp swings in recent years, and the latest pullback puts fresh focus on a simple question for investors: Is the current share price in line with what the company’s book value can support, or has the stock moved away from its balance sheet fundamentals? Over the past 5 years, Uranium Energy has returned about 234.8%, which puts significant weight on whether the balance sheet can justify where the equity now trades. The business relies heavily on the value of its...

Recent trading in Celcuity (CELC) has drawn attention after the share price closed at $80.61. The biotechnology company is still at a clinical stage and reports no revenue but continues to incur net losses. Short term trading in Celcuity has cooled, with the share price down 5.06% over the past day and 11.0% over the past month. However, the 1 year total shareholder return of 55.38% and roughly 7x total return over three years indicate that longer term momentum has been strong. Spot fresh...

Bunge Global raised its full-year 2026 adjusted EPS guidance to a range of $9.25 to $9.75 after stronger soybean and softseed processing results, while acknowledging softer grain merchandising and higher integration and financing costs. The company is ahead of plan on Viterra cost synergies, now targeting about $350 million. This highlights both execution progress and the importance of turning processing gains into steadier earnings and better cash conversion. We will now examine how Bunge...

Huntsman (HUN) has drawn attention after recent share price weakness, with the stock closing at $9.09. Investors are reassessing the chemical producer as returns over the past month and past three months have declined. Recent trading has extended that weaker tone, with Huntsman’s share price return down 4.7% over the past week, 10.7% over the past month, and 24.7% over the past quarter. The 3 year total shareholder return is lower by 56.6%, signalling fading momentum and a cautious reset of...

Utz Brands (UTZ) reaffirmed its regular shareholder payout, with the board declaring a quarterly cash dividend of about $0.063 per Class A share, payable on October 1, 2026. The dividend announcement comes as Utz Brands trades at US$14.24, with the share price delivering a 90 day return of about 102% and a year to date share price return of 38.39%. The 1 year total shareholder return of 14.17% contrasts with a 5 year total shareholder return that is down 12.58%, suggesting recent momentum has...

Amylyx Pharmaceuticals disclosed past agreements with Bachem Americas and a term sheet with Polypeptide Group to supply avexitide from 2028, including minimum annual purchase quantities, volume based pricing and a US$30 million upfront capacity reservation fee. The long term, non exclusive manufacturing setup and binding supply forecasts indicate that Amylyx is committing real cash and operational planning to the potential commercialization of avexitide, while maintaining flexibility with...

Brookfield Infrastructure Partners (NYSE:BIP) has drawn fresh attention after a 38.5% total return over three years, which has raised questions about whether its long-lived asset model adequately supports the current unit price. In the shorter term, the 1 month share price return is down 8.5% and the 3 month share price return is down 4%, while the year to date share price return is 5.2% and the 1 year total shareholder return is 22.3%. This indicates that momentum for Brookfield...

Fresh analyst commentary has pushed Americold Realty Trust (COLD) into focus, highlighting what is described as a highly undervalued stock with a strong earnings outlook and valuation ratios below sector averages. Short-term sentiment around Americold Realty Trust has cooled, with the 1-day share price return down 3.03% and the 30-day share price return down 4.44%. However, the year-to-date share price return is up 11.36% and the 1-year total shareholder return is 20.53%, suggesting...

Charles River Laboratories International recently introduced rapid cell banking programs that combine rapid microbiological methods with CGMP-compliant Next-Generation Sequencing to shorten cell bank timelines and support quality, safety, and regulatory readiness for biologics and advanced therapies. The new platform, strengthened by the Pathoquest acquisition and by Charles River’s Alternative Methods Advancement Project focus, tightens end-to-end biologics capabilities while supporting a...

Otis Worldwide disclosed that long-serving Chair, President and CEO Judy Marks plans to retire after her successor is appointed, with a search under way and a transition period running through July 31, 2027. Under Marks, Otis Worldwide focused heavily on its higher margin Service business and capital returns, including US$3.4b in dividends and US$5b in buybacks. This frames investor attention on how a new leader might treat cash allocation and the service portfolio. We will now look at how...

MPLX LP previously held its 2026 third quarter earnings call and, around the same period, management outlined a plan to grow cash distributions by 12.5% in both 2026 and 2027, alongside making related financial materials available to investors online. This explicit 2 year distribution growth target gives unitholders clearer visibility on MPLX’s capital return priorities and how management balances growth projects, leverage, and cash returns in a capital intensive midstream business. We will...

Inflation in August did not quietly slip back toward the Fed’s 2% target. It stayed stubborn, with gasoline costs jumping and feeding through to transport, freight and almost everything that needs to move. That kind of squeeze can punish some sectors while opening the door for others that sit closer to the source of those rising energy bills. This article walks through three U.S. energy producer and refiner stocks that appear especially exposed to this latest inflation shock, and explains why...

Synopsys continues to post earnings and revenue that exceed analyst expectations, with recent upward revisions to earnings estimates pointing to stronger operational execution than previously modeled. The company’s Zacks Rank #2 and consistently positive estimate revisions highlight how Synopsys’ tools remain deeply embedded in customers’ chip design workflows, supporting a robust fundamental demand backdrop. We will now examine how Synopsys’ investment narrative is shaped by rising earnings...

BeOne Medicines (ONC) has been drawing investor attention after a recent rebranding from BeiGene and a move to an AG structure, shifting focus toward its oncology portfolio and global partnerships. Recent trading paints a mixed picture for BeOne Medicines. The share price is around US$350.84 after a small 1-day decline of 0.74%, with a 90-day share price return of 29.87% and a 1-year total shareholder return of 4.92%. However, the 3-year total shareholder return of 84.09% contrasts with a...

Banc of California recently reported a second quarter net loss of US$251.3 million after repositioning securities and selling loans as part of a balance sheet reset, while loan and deposit volumes, net interest income, and problem loan metrics moved in a healthier direction. The report shows a sharp accounting hit tied to portfolio moves. At the same time, the underlying banking franchise of Banc of California is tracking toward stronger core lending and funding trends with fewer troubled...

Neurocrine Biosciences reported Phase 4 KINECT-PRO data in August showing INGREZZA delivers clinically measured and patient-reported relief in tardive dyskinesia, and management raised full-year guidance while highlighting portfolio additions CRENESSITY and VYKAT XR. The combination of early symptom relief reported by patients and higher INGREZZA guidance reflects demand resilience and broader franchise depth for Neurocrine Biosciences beyond a single neurology product. We will now look at...

BASF Catalysts LLC reported that Cheniere Energy has commissioned Durasorb LNG MAX technology across multiple liquefaction trains at its Corpus Christi LNG facility in Texas, with full deployment at the site targeted by the end of 2027. This rollout gives Cheniere Energy a single-unit process to remove heavy hydrocarbons, BTEX and water to cryogenic specifications, aiming to cut freeze related outages and keep LNG production schedules more predictable. We will now look at how Cheniere...

Provident Financial Services (PFS) is back in focus after its recent trading session, with shares closing at US$23.06. The move comes against a backdrop of mixed short term returns and stronger longer term performance. Over the past month the 2.7% decline in Provident Financial Services’ share price contrasts with a year to date share price return of 16.8%, while a 1 year total shareholder return of 21.1% and 3 year total shareholder return of 77.1% point to momentum that has been building...

Why Central Bancompany’s Latest Quarter Matters For Investors Central Bancompany (CBC) kicked off August with second quarter results that outperformed both the prior quarter and last year, paired with a fresh $100 million buyback and its usual quarterly dividend. Central Bancompany’s share price has climbed 33.54% year to date and delivered a 69.81% total shareholder return over the past year, while the recent 12.82% 90 day share price return suggests that momentum has been building into...

Federated Hermes has attracted renewed attention after analysts raised earnings estimates and highlighted the firm's strong return on equity and relatively low forward P/E of 9.9x, alongside support from ongoing share buybacks. The mix of heavy recent selling, an oversold RSI reading, and a Zacks Rank #2 rating has put Federated Hermes at the center of a debate about whether its current valuation still matches its underlying business strength. We will now look at how the investment narrative...

Teradata (TDC) moved into focus after President and CEO Stephen McMillan sold 10,000 shares on September 15, 2026, under a Rule 10b5-1 trading plan, a pre-arranged, non-discretionary transaction. Teradata’s recent insider sale occurs against a mixed price backdrop, with the share price at US$28.89 after a 7 day share price return of 3.77%, a 90 day share price decline of 6.44%, and a 1 year total shareholder return of 31.32%. Together, these figures suggest that shorter term momentum has...

When U.S. Treasury borrowing runs into the trillions and 10 year yields press toward 5%, the bond market starts to rewrite the playbook for almost every stock on your screen. Higher funding costs, heavier corporate bond issuance, and debt fueled AI build outs are quietly reshaping who gains and who struggles. This piece unpacks that story and highlights 3 stocks directly exposed to these forces, all identified as potential beneficiaries of this bond market shake up. The three businesses...

Cleveland-Cliffs has carried investors through a mixed journey, with periods of gains punctuated by longer stretches of weaker performance. This puts fresh focus on what buyers today are paying for its sales. With the share price around US$12.50 at the last close, the key question is how that market value lines up against the revenue the business is generating. Over the past 5 years, the stock has delivered a return of about 39% in declines, which makes the current pricing of its sales a...

Plains GP Holdings (PAGP) has drawn fresh attention after recent trading left the units around $27.67, with returns over the past month and past three months outpacing the shorter-term moves. That recent pullback sits against a much stronger backdrop. Plains GP Holdings has posted a 6.0% 1-month share price return, a 19.0% move over 3 months, and a 42.6% year-to-date gain, while a 1-year total shareholder return of 63.2% and a 5-year total shareholder return of 273.7% point to momentum that...